The chloride channel: pathology and specific therapy

Jane C. Davies (London, United Kingdom)

Source: International Congress 2015 – Cystic fibrosis: not just for the specialists
Session: Cystic fibrosis: not just for the specialists
Session type: Symposium
Number: 4742

WebcastSlide presentationMultimedia files

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Jane C. Davies (London, United Kingdom). The chloride channel: pathology and specific therapy. International Congress 2015 – Cystic fibrosis: not just for the specialists

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Molecular physiology of oxygen-sensitive potassium channels
Source: Eur Respir J 2001; 18: 221-227
Year: 2001



Dehydroepiandrosterone sulphate reduces chronic hypoxic pulmonary hypertension in rats
Source: Eur Respir J 2003; 21: 862-865
Year: 2003



Channelopathies in bronchiectasis
Source: Eur Respir Mon 2011; 52: 150-162
Year: 2011


TASK-1 (KCNK3) channels in the lung: from cell biology to clinical implications
Source: Eur Respir J, 50 (5) 1700754; 10.1183/13993003.00754-2017
Year: 2017



Effects of duramycin on cardiac voltage-gated ion channels
Source: Annual Congress 2009 - Cystic fibrosis: understanding a complex disease
Year: 2009


Calcium channels‘ blockers in therapy of COPD patients
Source: Eur Respir J 2006; 28: Suppl. 50, 31s
Year: 2006

Genetic alteration in the mammalian chloride channel CLNS1A alter lung function in children
Source: Eur Respir J 2006; 28: Suppl. 50, 476s
Year: 2006

The pathophysiological roles of a voltage-gated potassium channel Kv1.5 in toluene diisocyanate-induced asthma
Source: Eur Respir J 2002; 20: Suppl. 38, 29s
Year: 2002

CFTR dysfunction and its specific treatment
Source: International Congress 2018 – PG18 Cystic fibrosis: management in adult patients
Year: 2018


Preclinical evaluation of the epithelial sodium channel inhibitor BI 1265162 for treatment of cystic fibrosis
Source: ERJ Open Res, 6 (4) 00429-2020; 10.1183/23120541.00429-2020
Year: 2020



Role of NO pathway, calcium and potassium channels in the peripheral pulmonary vascular tone in dogs
Source: Eur Respir J 2001; 17: 20-26
Year: 2001



Exercise reduces airway sodium ion reabsorption in cystic fibrosis but not in exercise asthma
Source: Eur Respir J 2011; 37: 342
Year: 2011



Late-breaking abstract: Pre-clinical characterization of RP3128, a novel and potent CRAC channel inhibitor for the treatment of respiratory disorders
Source: Annual Congress 2011 - Late-Breaking Abstracts Session: New treatments and targets for airway disease
Year: 2011


Effect of the KCa3.1 k+ channels blocker triarylmethane-34 in a murine model of chronic asthma
Source: Annual Congress 2009 - COPD and asthma - from the cell to the clinic
Year: 2009


Novel oral voltage-gated sodium channel (Nav) inhibitors inhibit capsaicin induced cough in conscious guinea pigs
Source: International Congress 2015 – New models for treating airway diseases
Year: 2015

Identification of a TRPM7-like non-selective cation channel in human lung mast cells
Source: Eur Respir J 2004; 24: Suppl. 48, 453s
Year: 2004

Properties of a store-operated no nselective cation channel in airway smooth muscle
Source: Eur Respir J 2008; 32: 1529-1538
Year: 2008



SUR1/Kir6.2 potassium channel a new actor involved in pulmonary arterial hypertension
Source: Virtual Congress 2020 – Pathophysiology of pulmonary hypertension
Year: 2020


ENaC inhibition in cystic fibrosis: potential role in the new era of CFTR modulator therapies
Source: Eur Respir J, 56 (6) 2000946; 10.1183/13993003.00946-2020
Year: 2020



Expression of HCLCA1, a calcium activated chloride channel upregulated in the airway of asthmatic patients
Source: Eur Respir J 2002; 20: Suppl. 38, 572s
Year: 2002